Natural products as sources of new drugs over the 30 years from 1981 to 2010

Author(s): Newman DJ, Cragg GM

Abstract

This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003, and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1, 1981, to December 31, 2010, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs worldwide. We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions and have added a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131, or 74.8%, are other than "S" (synthetic), with 85, or 48.6%, actually being either natural products or directly derived therefrom. In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.

Similar Articles

Producing drugs from marine sponges

Author(s): Belarbi el H, Contreras Gómez A, Chisti Y, García Camacho F, Molina Grima E

Marine sponges as pharmacy

Author(s): Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH

Anti-biofilm compounds derived from marine sponges

Author(s): Stowe SD, Richards JJ, Tucker AT, Thompson R, Melander C, et al.

Biogeography of sponge chemical ecology: comparisons of tropical and temperate defenses

Author(s): Becerro MA, Thacker RW, Turon X, Uriz MJ, Paul VJ

Porifera: Sponges

Author(s): Lavrov D

Drug development from marine natural products

Author(s): Molinski TF, Dalisay DS, Lievens SL, Saludes JP

Marine natural products as anticancer drugs

Author(s): Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH

Approaches to identify, clone, and express symbiont bioactive metabolite genes

Author(s): Hildebrand M, Waggoner LE, Lim GE, Sharp KH, Ridley CP, et al.

The value of natural products to future pharmaceutical discovery

Author(s): Baker DD, Chu M, Oza U, Rajgarhia V

Antiviral lead compounds from marine sponges

Author(s): Sagar S, Kaur M, Minneman KP

Current status on natural products with antitumor activity from Brazilian marine sponges

Author(s): Frota MJ, Silva RB, Mothes B, Henriques AT, Moreira JC

Marine natural products

Author(s): Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR

Bioactive indole derivatives from the South Pacific marine sponges Rhopaloeides odorabile and Hyrtios sp

Author(s): Longeon A, Copp BR, Quévrain E, Roué M, Kientz B, et al.

Isolation of steroidal glycosides from the Caribbean sponge Pandaros acanthifolium

Author(s): Berrué F, McCulloch MW, Boland P, Hart S, Harper MK, et al.

The odyssey of marine pharmaceuticals: a current pipeline perspective

Author(s): Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, et al.

Monanchocidin: a new apoptosis-inducing polycyclic guanidine alkaloid from the marine sponge Monanchora pulchra

Author(s): Guzii AG, Makarieva TN, Denisenko VA, Dmitrenok PS, Kuzmich AS, et al.

The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis

Author(s): Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, et al.

New lysophosphatidylcholines and monoglycerides from the marine sponge Stelletta sp

Author(s): Zhao Q, Mansoor TA, Hong J, Lee CO, Im KS, et al.